Hypertrophic Cardiomyopathy
Despite advances in hcm treatments, unmet needs still exist
Hypertrophic Cardiomyopathy (HCM) is the most common form of genetic heart disease, affecting approximately one in 500 people, and is associated with reduced quality of life and an elevated risk of heart failure, abnormal heart rhythms, and sudden cardiac death (SCD).
HCM is chronic and progressive in nature and people with HCM may have a higher risk of heart failure, stroke, and atrial fibrillation. Commonly experienced symptoms include breathlessness, irregular heartbeats, chest pain, tiredness, dizziness, or even fainting. These symptoms are caused by excessive contraction and thickening (hypertrophy) of the left ventricular wall of the heart. Over time, the thickened muscle becomes stiff, making it difficult for the heart to relax and fill with blood. This is known as “diastolic dysfunction.” It is important for individuals experiencing these symptoms to check with their doctor. The doctor will review the individuals’ heart health, their family heart health history and may recommend a genetic test.
Two major forms of HCM include obstructive (oHCM) and non-obstructive (nHCM) hypertrophic cardiomyopathy. oHCM pathology is observed in two thirds, while nHCM is present in one third of all individuals with HCM.
Healthy Heart vs. Heart with HCM
Slide to view more
About HCM
A severe, inherited heart disease
HCM is chronic, progressive and can increase the risk of heart failure, stroke, and sudden cardiac death (SCD). Many living with the disease may not know it until they present with severe symptoms, including SCD.
Characterized by diastolic dysfunction
Excessive thickening of the left ventricular wall leads to an inability of the heart to fill with blood during each beat, which can cause symptoms like breathlessness, irregular heartbeats, chest pain, tiredness, dizziness, or even fainting.
Two important subtypes: nHCM & oHCM
Symmetrical wall thickening is seen in non-obstructive HCM (nHCM); obstructive HCM (oHCM) is characterized by asymmetrical wall thickening.
EDG-7500
EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, intended to slow the excessive rate of early contraction and improve impaired cardiac relaxation associated with obstructive and non-obstructive HCM, and with other diseases of diastolic dysfunction.
EDG-7500 is an investigational therapy that has not been approved for use in HCM or any cardiac disease by any regulatory agency, as its safety and effectiveness have not been established for the treatment of these diseases.
